
Christina Bradley
Examiner (ID: 2253, Phone: (571)272-9044 , Office: P/1675 )
| Most Active Art Unit | 1654 |
| Art Unit(s) | 1675, 1654 |
| Total Applications | 1470 |
| Issued Applications | 827 |
| Pending Applications | 184 |
| Abandoned Applications | 516 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19226711
[patent_doc_number] => 12006344
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-11
[patent_title] => MIC-1 compounds and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/083811
[patent_app_country] => US
[patent_app_date] => 2022-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 15198
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18083811
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/083811 | MIC-1 compounds and use thereof | Dec 18, 2022 | Issued |
Array
(
[id] => 18597271
[patent_doc_number] => 20230272066
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER, INFECTIONS AND AUTOIMMUNE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/084155
[patent_app_country] => US
[patent_app_date] => 2022-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12424
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18084155
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/084155 | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders | Dec 18, 2022 | Issued |
Array
(
[id] => 19246828
[patent_doc_number] => 20240197812
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => Methods of Treating Cardiac Injury
[patent_app_type] => utility
[patent_app_number] => 18/079545
[patent_app_country] => US
[patent_app_date] => 2022-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13148
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18079545
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/079545 | Methods of Treating Cardiac Injury | Dec 11, 2022 | Pending |
Array
(
[id] => 19246828
[patent_doc_number] => 20240197812
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => Methods of Treating Cardiac Injury
[patent_app_type] => utility
[patent_app_number] => 18/079545
[patent_app_country] => US
[patent_app_date] => 2022-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13148
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18079545
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/079545 | Methods of Treating Cardiac Injury | Dec 11, 2022 | Pending |
Array
(
[id] => 18738038
[patent_doc_number] => 20230346947
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF LAR FAMILY PHOSPHATASES
[patent_app_type] => utility
[patent_app_number] => 17/987137
[patent_app_country] => US
[patent_app_date] => 2022-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20922
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17987137
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/987137 | Compositions and methods for inhibiting the activity of LAR family phosphatases | Nov 14, 2022 | Issued |
Array
(
[id] => 18308611
[patent_doc_number] => 20230112511
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => LIQUID BANDAGE CONTAINING PEPTIDE ANTI-INFLAMMATORY ACTIVE INGREDIENTS AND PREPARATION METHOD THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/053765
[patent_app_country] => US
[patent_app_date] => 2022-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3545
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053765
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/053765 | LIQUID BANDAGE CONTAINING PEPTIDE ANTI-INFLAMMATORY ACTIVE INGREDIENTS AND PREPARATION METHOD THEREOF | Nov 8, 2022 | Pending |
Array
(
[id] => 18869823
[patent_doc_number] => 11857603
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-02
[patent_title] => PTH compounds with low peak-to-trough ratios
[patent_app_type] => utility
[patent_app_number] => 18/053701
[patent_app_country] => US
[patent_app_date] => 2022-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34631
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 159
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053701
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/053701 | PTH compounds with low peak-to-trough ratios | Nov 7, 2022 | Issued |
Array
(
[id] => 19157690
[patent_doc_number] => 20240150397
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR
[patent_app_type] => utility
[patent_app_number] => 18/050964
[patent_app_country] => US
[patent_app_date] => 2022-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53129
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050964
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/050964 | Targeted delivery system and methods of use therefor | Oct 27, 2022 | Issued |
Array
(
[id] => 18323921
[patent_doc_number] => 20230122049
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => METHOD AND COMBINATION FOR THE SUPPRESSION OF COVID-19 VIRUS
[patent_app_type] => utility
[patent_app_number] => 18/048262
[patent_app_country] => US
[patent_app_date] => 2022-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6393
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048262
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/048262 | Method and combination for the suppression of COVID-19 virus | Oct 19, 2022 | Issued |
Array
(
[id] => 18323921
[patent_doc_number] => 20230122049
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => METHOD AND COMBINATION FOR THE SUPPRESSION OF COVID-19 VIRUS
[patent_app_type] => utility
[patent_app_number] => 18/048262
[patent_app_country] => US
[patent_app_date] => 2022-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6393
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048262
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/048262 | Method and combination for the suppression of COVID-19 virus | Oct 19, 2022 | Issued |
Array
(
[id] => 18309917
[patent_doc_number] => 20230113817
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => DILEUCINE COMPOSITIONS AND METHODS OF USE THEREOF FOR FAT LOSS
[patent_app_type] => utility
[patent_app_number] => 17/964903
[patent_app_country] => US
[patent_app_date] => 2022-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7172
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17964903
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/964903 | DILEUCINE COMPOSITIONS AND METHODS OF USE THEREOF FOR FAT LOSS | Oct 11, 2022 | Abandoned |
Array
(
[id] => 18947042
[patent_doc_number] => 11890315
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-06
[patent_title] => Stable ascorbic acid compositions and methods of using same
[patent_app_type] => utility
[patent_app_number] => 17/938861
[patent_app_country] => US
[patent_app_date] => 2022-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 20
[patent_no_of_words] => 24312
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938861
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/938861 | Stable ascorbic acid compositions and methods of using same | Oct 6, 2022 | Issued |
Array
(
[id] => 18389909
[patent_doc_number] => 20230158127
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/932230
[patent_app_country] => US
[patent_app_date] => 2022-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40079
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17932230
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/932230 | COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES | Sep 13, 2022 | Abandoned |
Array
(
[id] => 18374426
[patent_doc_number] => 20230149505
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => HMGB1 ANTAGONIST TREATMENT OF SEVERE SEPSIS
[patent_app_type] => utility
[patent_app_number] => 17/898994
[patent_app_country] => US
[patent_app_date] => 2022-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42872
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 535
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17898994
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/898994 | HMGB1 antagonist treatment of severe sepsis | Aug 29, 2022 | Issued |
Array
(
[id] => 19311602
[patent_doc_number] => 12037405
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-16
[patent_title] => Anti-CD70 antibody drug conjugates
[patent_app_type] => utility
[patent_app_number] => 17/898384
[patent_app_country] => US
[patent_app_date] => 2022-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 11
[patent_no_of_words] => 68760
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 352
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17898384
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/898384 | Anti-CD70 antibody drug conjugates | Aug 28, 2022 | Issued |
Array
(
[id] => 18126500
[patent_doc_number] => 20230012121
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-12
[patent_title] => COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/893944
[patent_app_country] => US
[patent_app_date] => 2022-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21553
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 125
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17893944
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/893944 | COMPOUNDS | Aug 22, 2022 | Issued |
Array
(
[id] => 18484906
[patent_doc_number] => 20230212220
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => METHODS FOR REDUCING CD36 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/880271
[patent_app_country] => US
[patent_app_date] => 2022-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9794
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17880271
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/880271 | METHODS FOR REDUCING CD36 EXPRESSION | Aug 2, 2022 | Abandoned |
Array
(
[id] => 17988889
[patent_doc_number] => 20220354926
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => OPHTHALMIC COMPOSITIONS COMPRISING CICLOSPORIN
[patent_app_type] => utility
[patent_app_number] => 17/814818
[patent_app_country] => US
[patent_app_date] => 2022-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5519
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814818
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/814818 | OPHTHALMIC COMPOSITIONS COMPRISING CICLOSPORIN | Jul 24, 2022 | Abandoned |
Array
(
[id] => 19855598
[patent_doc_number] => 12258422
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-25
[patent_title] => Cyclopeptide and method for preparing the same
[patent_app_type] => utility
[patent_app_number] => 17/864829
[patent_app_country] => US
[patent_app_date] => 2022-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 2
[patent_no_of_words] => 5500
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 240
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17864829
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/864829 | Cyclopeptide and method for preparing the same | Jul 13, 2022 | Issued |
Array
(
[id] => 18179507
[patent_doc_number] => 20230040236
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications
[patent_app_type] => utility
[patent_app_number] => 17/811625
[patent_app_country] => US
[patent_app_date] => 2022-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29549
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811625
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/811625 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | Jul 10, 2022 | Pending |